Effect of Quercetin Supplementation on Endometriosis Outcomes
- Conditions
- Endometriosis
- Interventions
- Other: PlaceboDietary Supplement: Quercetin
- Registration Number
- NCT05983224
- Lead Sponsor
- National Nutrition and Food Technology Institute
- Brief Summary
Quercetin is a polyphenol compound that possesses anti-inflammatory properties and can be found in various food sources like apples, berries, cabbage, and onions. In Park et al.'s study, it was discovered that quercetin led to a significant decrease in the proliferation of endometriosis cells. Furthermore, quercetin also triggered apoptosis in endometriosis cells in vitro and reduced the size of endometriosis lesions in vivo. Nevertheless, as of now, there have been no studies conducted in Iran or worldwide that explore the effects of quercetin supplementation on individuals with endometriosis. Hence, the aim of this study is to investigate the impact of quercetin supplementation on factors such as glycemic status, lipid profile, oxidative stress, inflammation, growth factors, adiponectin, sex hormones, and anthropometric indicators in women suffering from endometriosis.
- Detailed Description
The participants in the study were randomly assigned to two groups: the intervention group and the control group. The intervention group will receive two 500 mg quercetin tablets daily, after breakfast and lunch, for twelve weeks. On the other hand, the control group will be given a placebo. Blood samples will be collected before and after the intervention to measure changes in blood lipid profile, fasting blood sugar, sex hormones (testosterone, estrogen, progesterone), TNFα, IL-6, adiponectin, IGF1, HbA1C, SHBG, FSH, LH, and plasma total antioxidant capacity.
Recruitment & Eligibility
- Status
- RECRUITING
- Sex
- Female
- Target Recruitment
- 50
- Willing to cooperate and complete the informed consent form.
- Diagnosed endometriosis using laparoscopy and histopathological tests.
- In the age group of 18 to 40 years.
- Having a regular menstrual cycle.
- Having a body mass index between 18.5 and 30.
- Using hormonal medications or intrauterine treatments for a minimum of three months prior to collecting a sample.
- Having immune system disorders, persistent infections, diabetes, or any conditions like polyps and fibroids within the uterine cavity.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Placebo Placebo The Placebogroup will receive Placebo tablets daily, after breakfast and lunch, for twelve weeks. Quercetin Quercetin The intervention group will receive two 500 mg quercetin tablets daily, after breakfast and lunch, for twelve weeks.
- Primary Outcome Measures
Name Time Method Mean serum TNF-alpha concentration 12 weeks Human Tumor Necrosis Factor Αlpha, TNF-A ELISA Kit
Mean serum IL-6 concentration 12 weeks Human Interleukin 6, IL-6 ELISA Kit
- Secondary Outcome Measures
Name Time Method Mean Serum Testosterone concentration 12 weeks The Testosterone ELISA Kits
Mean Serum Estrogen concentration 12 weeks The Total Estrogens ELISA Assay Kit
Mean Serum FSH concentration 12 weeks FSH (Human) ELISA Kit
Mean HbA1C Serum 12 weeks Human Hemoglobin A1c (HbA1c) Assay Kit
Mean Serum Adiponectin concentration 12 weeks Adiponectin Human ELISA Kit
Mean Serum Progesterone concentration 12 weeks The Progesterone Enzyme Immunoassay Kit
Mean Serum FBS concentration 12 weeks Glucose Test Kit
Mean Serum SHBG concentration 12 weeks liquid chromatography-tandem mass spectrometry
Mean plasma total antioxidant capacity concentration 12 weeks Total Antioxidant Capacity ELISA Kit
Mean Serum IGF1 concentration 12 weeks IGF-1 ELISA Assay Kit
Mean Serum LH concentration 12 weeks LH (Human) ELISA Kit
Trial Locations
- Locations (1)
National Nutrition and Food Technology Research Institute
🇮🇷Tehran, Iran, Islamic Republic of